ARCH — Arch Biopartners Income Statement
0.000.00%
Last trade - 00:00- CA$120.61m
- CA$123.46m
- CA$2.12m
Annual income statement for Arch Biopartners, fiscal year end - September 30th, CAD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.068 | 3.89 | 0.965 | 1.98 | 2.12 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Operating Interest Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4.7 | 5.05 | 2.35 | 5.34 | 6.07 |
| Operating Profit | -4.63 | -1.16 | -1.39 | -3.36 | -3.95 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -4.63 | -1.17 | -1.41 | -3.33 | -3.92 |
| Net Income After Taxes | -4.63 | -1.17 | -1.41 | -3.33 | -3.92 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.63 | -1.17 | -1.41 | -3.33 | -3.92 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.63 | -1.17 | -1.41 | -3.33 | -3.92 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.077 | -0.019 | -0.023 | -0.053 | -0.062 |